Showing results (81-90 of 113) with videos related to

Sort By:
Pageof 12
Addiction Biology|July 19, 2011
Extended access cocaine self-administration differentially activates dorsal raphe and amygdala corticotropin-releasing factor systems in ratsEric P Zorrilla, Sunmee Wee, Yu Zhao, et al.
Alcoholism, Clinical and Experimental Research|September 11, 2009
Operant behavior and alcohol levels in blood and brain of alcohol-dependent ratsNicholas W Gilpin, Amanda D Smith, Maury Cole, et al.
Research Square|March 10, 2025
Motivating Effects of Negative-hedonic Valence Encoded in EngramsHermina Nedelescu, Elias Meamari, Nami Rajaei, et al.
Biological Psychiatry Global Open Science|October 1, 2025
Recruitment of Neuronal Populations in the Paraventricular Thalamus of Alcohol-Seeking Rats With Withdrawal-Related Learning ExperienceHermina Nedelescu, Elias Meamari, Nami Rajaei, et al.
Biorxiv : the Preprint Server for Biology|March 10, 2025
Motivating Effects of Negative-hedonic Valence Encoded in EngramsHermina Nedelescu, Elias Meamari, Nami Rajaei, et al.
Neuropharmacology|June 16, 2023
Strain and sex-related behavioral variability of oxycodone dependence in ratsMichelle R Doyle, Angelica R Martinez, Ran Qiao, et al.
Addiction Biology|September 24, 2017
Phosphorylation of calcium/calmodulin-dependent protein kinase II in the rat dorsal medial prefrontal cortex is associated with alcohol-induced cognitive inflexibilityLuis A Natividad, Michael Q Steinman, Sarah A Laredo, et al.
British Journal of Pharmacology|December 2, 2021
Genetic deletion or pharmacological blockade of nociceptin/orphanin FQ receptors in the ventral tegmental area attenuates nicotine-motivated behaviourAna Domi, Veronica Lunerti, Michele Petrella, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|May 28, 2014
Chronic treatment with novel brain-penetrating selective NOP receptor agonist MT-7716 reduces alcohol drinking and seeking in the ratRoberto Ciccocioppo, Serena Stopponi, Daina Economidou, et al.
Neuropharmacology|June 20, 2024
Cebranopadol, a novel long-acting opioid agonist with low abuse liability, to treat opioid use disorder: Preclinical evidence of efficacyNazzareno Cannella, Veronica Lunerti, Qianwei Shen, et al.
Pageof 12